Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial
Authors' conclusion
Thus, intermittent D + Q treatment did not reduce bone resorption in the overall group of postmenopausal women.
Study context
- Population
- Postmenopausal women
- Participants
- 60 women
- Comparison
- Intermittent dasatinib plus quercetin vs control
- Primary endpoint
- % change in bone resorption marker CTX
- Follow-up
- 20 weeks
Methodological detailsphase 2
- Phase 2
Primary result
As reported in the abstract
% change in CTX
D + Q
−4.1%
median · IQR −13.2–2.6
Control
−7.7%
median · IQR −20.1–14.3
P = 0.611
Secondary outcomes
| Outcome | Relative change | P value |
|---|---|---|
| % change in bone formation marker P1NP, relative to control · 2 weeks | +16% | P = 0.020 |
| % change in P1NP, relative to control · 4 weeks | +16% | P = 0.024 |
| % change in P1NP, relative to control · 20 weeksNot different from control | −9% | P = 0.149 |
Exploratory: women with high senescent cell burden (highest tertile T cell p16 mRNA)
- P1NP increase with D + Q at 2 weeks (P = 0.035)
- +34%
- CTX reduction with D + Q at 2 weeks (P = 0.049)
- −11%
- Radius BMD increase with D + Q at 20 weeks (P = 0.004)
- +2.7%
- Exploratory analyses
Safety
- No serious adverse events were observed
Original publication
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med. Published 2 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →